{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:43:13Z","timestamp":1794472993742,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent trials of acute secondary prevention in patients with minor ischemic stroke or transient ischemic attack (TIA) have demonstrated high rates of early recurrence within days of the initial event. Identifying clinical features associated with early recurrence may guide focused management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using logistic regression applied to the data of the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, we evaluated what baseline clinical factors predict outcome events occurring within 7\u2009days of randomization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the POINT trial, 181 subjects (3.7%) had early recurrence, defined as primary outcome events within 7\u2009days of trial entry, whereas only 100 outcome events occurred over the remainder of the 90\u2009day trial. Protective effects of dual antiplatelet therapy with clopidogrel plus aspirin were seen only as a reduction in these early recurrences, without any impact on later events. In univariate analysis, systolic blood pressure, diastolic blood pressure, serum glucose, initial carotid imaging results, study cohort (minor stroke or TIA), and treatment assignment were significantly associated with early recurrence. Multivariate logistic regression analysis identified a number of factors with significant independent associations with early recurrence, including carotid stenosis or occlusion (Odds Ratio [OR] 2.77; 95% confidence interval [CI] 1.78\u20134.31), cohort (minor stroke versus TIA) (OR 1.86; 95% CI 1.33\u20132.58), race (OR 1.57; 95% CI 1.10\u20132.25), baseline statin use (OR 0.68; 95% CI 0.49\u20130.95), systolic blood pressure (OR 1.10; 95% CI 1.03\u20131.18), serum glucose (OR 1.03; 95% CI 1.01\u20131.05), and age (OR 1.02; 95% CI 1.00\u20131.03). Receiver Operator Characteristic (ROC) analysis showed a 70% accuracy of the resulting logistic model in predicting early recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Early recurrence is high, and is concentrated in the first 7\u2009days, in patients with minor stroke or TIA. A number of baseline clinical factors, including carotid disease, presentation with minor stroke rather than TIA, race, absence of statin usage, systolic blood pressure, and serum glucose, are independently associated with early event recurrence in the POINT trial population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02703-4","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T06:34:01Z","timestamp":1652510041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of very early stroke recurrence in the POINT trial population"],"prefix":"10.1186","volume":"22","author":[{"given":"Natalie","family":"Bourand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Brorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1161\/01.STR.0000080935.01264.91","volume":"34","author":"JK Lovett","year":"2003","unstructured":"Lovett JK, Dennis MS, Sandercock PA, et al. Very early risk of stroke after a first transient ischemic attack. Stroke. 2003;34:e138\u201340.","journal-title":"Stroke"},{"key":"2703_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/CIRCULATIONAHA.119.040713","volume":"140","author":"SC Johnston","year":"2019","unstructured":"Johnston SC, Elm JJ, Easton JD, et al. Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke. A secondary analysis from the POINT randomized trial. Circulation. 2019;140:658\u201364.","journal-title":"Circulation"},{"key":"2703_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang Y, Zhao X, CHANCE Investigators, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11\u20139.","journal-title":"N Engl J Med"},{"key":"2703_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute ischemic stroke or transient ischemic attack. N Engl J Med. 2016;375:35\u201343.","journal-title":"N Engl J Med"},{"key":"2703_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207\u201317.","journal-title":"N Engl J Med"},{"key":"2703_CR6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1161\/STROKEAHA.120.031447","volume":"52","author":"JR Brorson","year":"2021","unstructured":"Brorson JR, Bulwa ZB. Two-state kinetic model of rates of stroke recurrence in the POINT study population. Stroke. 2021;52:1446\u20139.","journal-title":"Stroke"},{"key":"2703_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","volume":"76","author":"Y Pan","year":"2019","unstructured":"Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack. A pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurol. 2019;76:1466\u201373.","journal-title":"JAMA Neurol"},{"key":"2703_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","volume":"379","author":"SC Johnston","year":"2018","unstructured":"Johnston SC, Easton JD, Farrant M, the POINT investigators, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379:215\u201325.","journal-title":"N Engl J Med"},{"key":"2703_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1161\/STROKEAHA.114.006886","volume":"46","author":"H Erdur","year":"2015","unstructured":"Erdur H, Scheitz JF, Ebinger M, et al. In-hospital stroke recurrence and stroke after transient ischemic attack. Frequency and risk factors. Stroke. 2015;46:1031\u20137.","journal-title":"Stroke"},{"key":"2703_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0140-6736(04)15785-1","volume":"363","author":"PM Rothwell","year":"2004","unstructured":"Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ, Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363:915\u201324.","journal-title":"Lancet."},{"issue":"8","key":"2703_CR11","first-page":"e1137","volume":"96","author":"H Kamel","year":"2020","unstructured":"Kamel H, Zhang C, Kleindorfer DO, et al. Association of black race with early recurrence after minor stroke or transient ischemic attack. Secondary analysis of the POINT randomized clinical trial. JAMA Neurol. 2020;96(8):e1137\u201344.","journal-title":"JAMA Neurol"},{"key":"2703_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/STROKEAHA.111.627729","volume":"43","author":"AC Flint","year":"2012","unstructured":"Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43:147\u201354.","journal-title":"Stroke"},{"key":"2703_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1212\/WNL.0b013e3181ca9cff","volume":"74","author":"H Ay","year":"2010","unstructured":"Ay H, Gungor L, Arsava EM, et al. A score to predict early risk of recurrence after ischemic stroke. Neurol. 2010;74:128\u201335.","journal-title":"Neurol"},{"key":"2703_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1161\/STROKEAHA.111.000141","volume":"44","author":"R Lemmens","year":"2013","unstructured":"Lemmens R, Smet S, Thijs VN. Clinical scores for predicting recurrence after transient ischemic attack or stroke: how good are they? Stroke. 2013;44:1198\u2013203.","journal-title":"Stroke"},{"key":"2703_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1212\/01.wnl.0000269789.09277.47","volume":"69","author":"M Blanco","year":"2007","unstructured":"Blanco M, Nombela F, Catellanos M, et al. Statin treatment withdrawal in ischemic stroke. A controlled randomized study. Neurology. 2007;69:904\u201310.","journal-title":"Neurology"},{"key":"2703_CR16","doi-asserted-by":"publisher","first-page":"701168","DOI":"10.3389\/fneur.2021.701168","volume":"12","author":"ZB Bulwa","year":"2021","unstructured":"Bulwa ZB, Mendelson SJ, Brorson JR. Acute secondary prevention of ischemic stroke: overlooked no longer. Front Neurol. 2021;12:701168.","journal-title":"Front Neurol"},{"key":"2703_CR17","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack. A guideline From the American Heart Association\/American Stroke Association. Stroke. 2021;52:e364\u2013467.","journal-title":"Stroke"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02703-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02703-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02703-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T06:34:33Z","timestamp":1652510073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02703-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02703-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were performed in accordance with relevant guidelines and regulations. The University of Chicago Institutional Review Board determined the present study to be exempt from further review (IRB20\u20130874). Informed consent was not obtained for this project because this was a retrospective analysis of existing deidentified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Natalie Bourand has no conflicts of interest to declare. James Brorson has provided medical-legal consultation and has served as a consultant for the National Peer Review Corporation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}